Yonsei Med J.  2007 Apr;48(2):233-239. 10.3349/ymj.2007.48.2.233.

Polymorphisms of CYP1A1 and GSTM1 Genes and Susceptibility to Oral Cancer

• Cha IH
• Park JY
• Chung WY
• Choi MA
• Kim HJ
• Park KK

• KMID: 1779525
• DOI: http://doi.org/10.3349/ymj.2007.48.2.233

Abstract

PURPOSE
Oral cancer is the fifth most common form of cancer in the world and comprises 6.5% of all cancer deaths. Since one of the major risk factors for oral cancer is tobacco use, we hypothesized that polymorphic genes coding for tobacco carcinogen-metabolizing enzymes may play a role in oral cancer susceptibility. MATERIALS AND METHODS: To investigate the association between polymorphisms of the CYP1A1 and GSTM1 genes and risks for oral squamous cell carcinoma (OSCC) in the Korean population, the prevalence of the CYP1A1 Mspl and GSTM1 null polymorphisms were examined in 72 patients with histologically confirmed primary OSCC, as well as in 221 healthy control subjects. RESULTS: A significant risk increase for oral cancer was observed among subjects with the homozygous CYP1A1 (m2/m2) genotype (OR=3.8, 95% CI=1.9-7.7), but not the GSTM1 null genotype (OR=0.7, 95% CI=0.4-1.3). Risk for oral cancer was significantly increased in subjects with the homozygous CYP1A1 (m2/m2)genotype, regardless of smoking history (smokers; OR=4.4; 95% CI=1.2-16.3; non- smokers OR=4.9; 95% CI=1.9-12.5). Using the potentially most protective genotype GSTM1 (+)/CYP1A1 [(m1/m1)+ (m1/m2)]as the reference group, an increased risk for oral cancer was observed among subjects with the GSTM1 (+)/ CYP1A1 (m2/m2) (OR= 2.0, 95% CI=0.8-5.2), and GSTM1 (-)/ CYP1A1 (m2/m2) (OR=4.9, 95% CI=1.5-15.5) genotypes (p < 0.009, (chi-square trend test). CONCLUSION: Our results suggest that individuals with a genotype of CYP1A1 (m2/m2) and GSTM1(-) are highly susceptible for OSCC and that the CYP1A1 (m2/m2) genotype is closely associated with increased risk of OSCC in Koreans.

Keyword

Tobacco carcinogen-metabolizing enzyme; CYP1A1; GSTM1; genetic polymorphism; oral squamous cell carcinoma

MeSH Terms

Smoking/epidemiology
Risk Factors
Mouth Neoplasms/epidemiology/*genetics
Middle Aged
Male
Humans
Homozygote
Glutathione Transferase/*genetics
Genotype
*Genetic Predisposition to Disease
Gene Deletion
Female
Cytochrome P-450 CYP1A1/*genetics
Aged, 80 and over
Aged
Adult

Reference

1. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res. 1991. 247:267–281.

2. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus AM, Hayes JD, et al. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis. 1995. 16:707–711.

3. Lin P, Wang SL, Wang HJ, Chen KW, Lee HS, Tsai KJ, et al. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer. 2000. 82:852–857.

4. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1995. 4:589–594.

5. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997. 9:733–743.

6. Sugimura H, Suzuki I, Hamada GS, Iwase T, Takahashi T, Nagura K, et al. Cytochrome P-450 lA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prev. 1994. 3:145–148.

7. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev. 1993. 2:481–485.

8. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev. 1997. 6:791–797.

9. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol. 1999. 35:191–196.

10. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis. 1999. 20:1927–1931.

11. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer. 1999. 83:606–609.

12. Phillips DH. Fifty years of benzo(a)pyrene. Nature. 1983. 303:468–472.

13. Rojas M, Cascorbi I, Alexandrov K, Kriek E, Auburtin G, Mayer L, et al. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis. 2000. 21:35–41.

14. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990. 263:131–133.

15. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991. 1:20–25.

16. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992. 1:485–489.

17. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996. 5:687–692.

18. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res. 1992. 83:866–870.

19. Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK, et al. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med. 2002. 31:505–511.

20. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995. 30:445–600.

21. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993. 85:1159–1164.

22. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev. 1998. 7:19–23.

23. Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr, et al. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics. 2000. 10:123–131.

24. Kihara M, Kihara M, Kubota A, Furukawa M, Kimura H. GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett. 1997. 112:257–262.

25. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTM3 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis. 2002. 23:803–807.

26. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTM3; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev. 1997. 6:901–905.

27. Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, et al. Glutathione S-transferase GSTM3 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 1996. 17:881–884.

28. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev. 1998. 7:719–724.

29. Ausubel FM, Brent R, Kingston R, Moore DD, Seidman JG, Smith JA. Current Protocols in Molecular Biology. 1988. Vol. 1. New York: John Wiley and Sons.

30. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem(Tokyo). 1991. 110:407–411.

31. SPSS. SPSS base 11.5 for windows, User's guide. 2003. Chicago: SPSS Inc..

32. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993. 53:2994–2999.

33. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994. 15:415–418.

34. Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. 2000. 36:267–271.

35. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSTM3 genes in Indian oral cancer. Oral Oncol. 2001. 37:593–598.

36. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002. 38:486–490.

37. Drummond SN, De Marco L, Noronha JC, Gomez RS. GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol. 2004. 40:52–55.

38. Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer. 2004. 109:95–101.

39. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxication enzymes in squamous cell carcinoma of the oral cavity. Oral Dis. 2003. 9:62–67.

40. Sikdar N, Mahmud SA, Paul RR, Roy B. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 2003. 195:33–42.